Clinical Trial Update: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) [Phase 1, Phase 2]

View source ↗

Summary

This is an update on a Phase 1/2a trial of PR001 (LY3884961) in Parkinson disease patients with a GBA1 mutation (PROPEL). The study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PR001 (LY3884961) (LY3884961)

Snippet

Sponsor: Prevail Therapeutics | Conditions: Parkinson Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING